A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor &agr; (pdgfr&agr;) monoclonal antibody, in advanced soft tissue sarcoma (sts)
Year: 2016
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Annals of Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, University of California, Los Angeles, University of Colorado Cancer Center, Washington University in St. Louis, Northwestern University, University Hospitals Cleveland Medical Center, Carolinas Healthcare System, Baptist MD Anderson Cancer Center, Eli Lilly (United States), Eli Lilly (United Kingdom), Columbia University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2587677492